Company expects to initiate registrational trial of ATYR1923 in pulmonary sarcoidosis in 2022
SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for its lead therapeutic candidate, ATYR1923, for the treatment of sarcoidosis. ATYR1923 is a potential first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory disease states. Clinical proof-of-concept was recently established for ATYR1923 in a Phase 1b/2a study in patients with pulmonary sarcoidosis, the main form of the disease, and the company expects to initiate a registrational trial in this indication this year.
The FDA’s Office of Orphan Drug Products grants orphan status to support the development of medicines for patients with unmet needs for rare disorders affecting fewer than 200,000 people in the United States. Orphan drug designation provides certain benefits, including the potential for seven years of market exclusivity following regulatory approval, exemption from FDA application fees and tax credits for qualified clinical trials.
“The receipt of orphan drug designation for ATYR1923 for sarcoidosis is an important milestone and recognizes the unmet need for the close to 200,000 patients living with this chronic, debilitating disease,” said Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr. “Current treatment options for patients with pulmonary sarcoidosis are limited. By reducing steroid burden while improving lung function and measures of sarcoidosis symptoms, ATYR1923 has the potential to be a transformative, disease modifying therapy with clinically meaningful outcomes for patients. We look forward to initiating a registrational trial in pulmonary sarcoidosis this year.”
Sarcoidosis is an inflammatory disease characterized by the formulation of granulomas, clumps of inflammatory cells, in one or more organs of the body. The lungs are affected in >90% of cases. Almost 200,000 Americans live with sarcoidosis and the prognosis ranges from benign and self-limiting to chronic, debilitating disease, in some cases with scarring of the lung, or fibrosis, resulting in permanent loss of lung function and death. Current treatment options include corticosteroids and other immunosuppressive therapies, which have limited efficacy and are associated with serious side-effects that many patients cannot tolerate long-term.
aTyr is developing ATYR1923 as a potential therapeutic for patients with severe inflammatory lung diseases. ATYR1923, a fusion protein comprised of the immuno-modulatory domain of histidyl-tRNA synthetase fused to the FC region of a human antibody, is a selective modulator of neuropilin-2 that downregulates innate and adaptive immune response in inflammatory disease states. aTyr’s lead indication for ATYR1923 is pulmonary sarcoidosis, a major form of interstitial lung disease. Clinical proof-of-concept for ATYR1923 was recently established in a Phase 1b/2a multiple-ascending dose, placebo-controlled study of ATYR1923 in patients with pulmonary sarcoidosis, which demonstrated safety and a consistent dose response and trends of benefit of ATYR1923 compared to placebo on key efficacy endpoints, including steroid reduction, lung function, clinical symptoms and inflammatory biomarkers.
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include statements regarding potential therapeutic benefits and applications of ATYR1923; timelines and plans with respect to certain development activities (such as the timing of additional clinical trials and planned interactions with regulatory authorities); and certain development goals. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding the COVID-19 pandemic, risks associated with the discovery, development and regulation of our product candidates, the risk that we or our partners may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Director, Investor Relations and Corporate Communications
Atlas Corp. ("Atlas") (NYSE: ATCO) announced today that its Board of Directors has declared cash dividends on its common and preferred shares as follows:
Every investor knows that the path toward profits lies in buying low and selling high. That’s a basic precept of any economic trading system. The trick, however, is recognizing when the stock is low enough to buy in. The prime moment to buy is when the stock hits bottom; that will maximize returns when the share price starts to rise again. There are a multitude of possible clues investors can use to find the price bottom; today, we’ll be looking at insider buying trends. Insiders – the corporate
(Bloomberg) — The head of India’s main medical research agency said there were “major safety concerns” over Merck & Co.’s Covid-19 drug that may impede its addition to the country’s viral treatment list.Even though India’s drug regulator last week approved Merck’s molnupiravir for emergency use, Balram Bhargava, the director general of the state-funded Indian Council of Medical Research, said the government has yet to decide on whether to recommend molnupiravir, even as coronavirus infection ra
Sutro stock collapsed Thursday — and was among the biggest biotech stock dives — after its ovarian cancer study disappointed investors.
Research Highlights: A laboratory study in mice with a bulging or weakening in the main artery supplying blood to the abdomen and legs – a condition known as abdominal aortic aneurysm – that were given sildenafil (a widely used erectile dysfunction…
The Omicron variant has quickly taken over the world, resulting in rising COVID cases, breakthrough infections, and reinfections. This new version of the virus has already pushed the U.S. to report more than one million new daily COVID cases on Jan. 3, and virus experts expect its surge to continue throughout the month, if not longer. More than 95 percent of cases in the country are estimated to be caused by Omicron, and every time the virus evolves, so can the illness it produces. According to
Clinical-stage biotech Aligos Therapeutics (NASDAQ: ALGS) had some bad news to report on Thursday. This was the issue with Aligos on Thursday; in the morning the company divulged that it is halting the further development of its experimental drug ALG-010133, which targets chronic hepatitis B (CHB). The decision was made based on data from a phase 1 study of the drug, which demonstrated that with ALG-010133, "at the projected efficacious dose … there is no meaningful [hepatitis B surface antigen] reduction" in patients with the disease.
(Bloomberg) — Sanofi formed a deal to develop 15 experimental oncology and immunology drugs with Exscientia Plc with possible total payouts of as much as $5.2 billion, allying with a company that uses artificial intelligence to make new medicines.The Oxford, England-based company will receive $100 million upfront, as well as milestone payments and royalties from successful treatments, the companies said Friday. This is the latest attempt by Sanofi Chief Executive Officer Paul Hudson to rejuvena
It has been a rough 12 months for Humanigen (HGEN), with shares down by 80%. Investors will be hoping 2022 will provide more joy; the company’s prospective Covid-19 treatment could go some way to changing sentiment around this beaten down name. On Wednesday, Humanigen announced it had reached its enrollment target in the Phase 2/3 ACTIV-5/BET-B trial assessing Covid-19 treatment lenzilumab in COVID-19 patients. There are now more than 400 patients in the primary analysis population – patients wi
The Cambridge drugmaker is just one of scores of Massachusetts-based biotech and health care companies that are scheduled to present at the conference.
(Bloomberg) — Hundreds of thousands of workers at iPhone maker Foxconn Technology Group and Huawei Technologies Co. are being tested for Covid-19 as China’s latest outbreak shows no signs of easing, with cases cropping up across the country and technology hub Shenzhen on high alert.The government in the eastern metropolis of Zhengzhou, known to locals as iPhone City, required that all residents be tested on Friday, including hundreds of thousands of employees on the local Foxconn campus. Huawei
Kansas City is facing a COVID testing frenzy, but when should you actually take a test? Does it matter what kind of test? We found some answers.
While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of Greater Boston life sciences and health care happenings.
After Annexon (NASDAQ: ANNX) revealed that this occurred in an otherwise encouraging study of its ANX005, a pipeline drug aimed at treating Huntington's disease, the company's shares tumbled by over 34% on the day. After market hours on Tuesday, Annexon reported interim results from an ongoing, open-label Phase 2 clinical trial of ANX005. The data concerned patients who completed the full 24-week course of treatment and revealed that the drug demonstrated "full target engagement of C1q in both serum and cerebrospinal fluid observed in evaluable patients through the dosing period."
(Reuters) -Pfizer Inc and Germany's BioNTech SE will develop an mRNA-based vaccine for viral infection shingles, collaborating for the third time after the success of their COVID-19 vaccine based on the same technology. Pfizer, which is making an equity investment worth $150 million for the latest deal, partnered with BioNTech in 2018 for an Influenza vaccine and again in 2020 for the COVID-19 shot that has been used across the world and has brought in billions in sales for the companies. The companies said on Wednesday they expect to begin clinical trials of the shingles vaccine, which will combine Pfizer's antigen technology and BioNTech's Messenger RNA platform technology, in the second half of 2022.
NEW YORK (Reuters) -Pfizer Inc expects the latest results from a clinical trial for kids under the age of 5 of the COVID-19 vaccine it developed with Germany's BioNTech SE by April, a top company scientist said on Wednesday. "The study has been amended to give a third dose to everybody who's less than five at least eight weeks after their last vaccination," Dr. Alejandra Gurtman, a Pfizer vaccine researcher said at a meeting of the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP). In December, Pfizer said it was changing the design of the trial because children between the ages of 2 and 4 who were given two 3-microgram doses of the vaccine did not have the same immune response that a larger dose of the vaccine generated in older children.
Mayo Clinic fires 700 unvaccinated employees
Germany's leaders are set to consider possible new restrictions and changes to quarantine rules on Friday as the new omicron variant advances quickly. Chancellor Olaf Scholz and the country’s 16 state governors are likely to build on restrictions introduced just after Christmas that limited private gatherings to 10 people, among other things. Scholz and the governors also are expected to consider shortening required quarantine or self-isolation periods that are currently as long as 14 days, something that many other countries already have done.
The Gavi vaccine alliance is in talks with India's Bharat Biotech over potential procurement of the company's Covaxin COVID-19 shot for the COVAX global vaccine distribution programme, a Gavi spokesperson told Reuters on Thursday. The World Health Organization in November gave Covaxin, India's first homegrown COVID-19 vaccine, approval for emergency use.
The Centers for Disease Control and Prevention is maintaining its position on its new COVID-19 isolation policy, with a slight update amid backlash.